Acadia Pharmaceuticals (ACAD) Accounts Payables (2010 - 2026)

Acadia Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 32.32% year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at $12.2 million (down 32.32% YoY), while the FY2025 annual figure was $10.9 million, down 32.66% from the prior year.
• Accounts Payables was $12.2 million for Q1 2026 at Acadia Pharmaceuticals, up from $10.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $21.7 million in Q3 2025 to a low of $10.0 million in Q3 2022.
• Historically, Accounts Payables has averaged $15.8 million across 5 years, with a median of $17.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 85.37% in 2022, then plunged 32.66% in 2025.
• A 5-year view of Accounts Payables shows it stood at $12.7 million in 2022, then soared by 37.64% to $17.5 million in 2023, then decreased by 7.7% to $16.2 million in 2024, then tumbled by 32.66% to $10.9 million in 2025, then grew by 12.32% to $12.2 million in 2026.
• The last three Accounts Payables figures came in at $12.2 million (Q1 2026), $10.9 million (Q4 2025), and $21.7 million (Q3 2025), per Business Quant data.